Millennium Management
SMMT icon

Millennium Management’s Summit Therapeutics SMMT Stock Holding History

Millennium Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.39M Sell
126,273
-342,744
-73% -$5.54M ﹤0.01% 3702
2025
Q4 		$8.2M Buy
469,017
+348,503
+289% +$6.56M ﹤0.01% 2479
2025
Q3 		$2.49M Sell
120,514
-435,495
-78% -$10.6M ﹤0.01% 3839
2025
Q2 		$11.8M Sell
556,009
-331,000
-37% -$7.55M 0.01% 2083
2025
Q1 		$17.1M Sell
887,009
-1,162,820
-57% -$23.3M 0.01% 1676
2024
Q4 		$36.6M Buy
2,049,829
+827,483
+68% +$16M 0.02% 1009
2024
Q3 		$26.8M Sell
1,222,346
-720,512
-37% -$10.1M 0.01% 1294
2024
Q2 		$15.2M Buy
+1,942,858
New +$10.5M 0.01% 1722
2023
Q3 		– Sell
-116,723
Closed -$293K – 6523
2023
Q2 		$293K Sell
116,723
-787,210
-87% -$1.44M ﹤0.01% 4905
2023
Q1 		$1.58M Buy
+903,933
New +$2.47M ﹤0.01% 3657
2022
Q4 		– Sell
-431,560
Closed -$514K – 7014
2022
Q3 		$514K Sell
431,560
-25,908
-6% -$29.3K ﹤0.01% 4953
2022
Q2 		$457K Buy
+457,468
New +$641K ﹤0.01% 5030
2021
Q2 		– Sell
-345,723
Closed -$2.03M – 7058
2021
Q1 		$2.03M Buy
345,723
+329,898
+2,085% +$2.13M ﹤0.01% 3520
2020
Q4 		$74K Buy
+15,825
New +$67K ﹤0.01% 5057
2018
Q3 		– Sell
-51,549
Closed -$126K – 4243
2018
Q2 		$126K Buy
51,549
+28,371
+122% +$363K ﹤0.01% 3627
2018
Q1 		$299K Sell
23,178
-76,695
-77% -$958K ﹤0.01% 3219
2017
Q4 		$1.11M Buy
99,873
+22,759
+30% +$254K ﹤0.01% 2642
2017
Q3 		$968K Buy
77,114
+1,291
+2% +$16.7K ﹤0.01% 2530
2017
Q2 		$864K Sell
75,823
-5,270
-6% -$59.3K ﹤0.01% 2519
2017
Q1 		$1.08M Sell
81,093
-14,079
-15% -$163K ﹤0.01% 2358
2016
Q4 		$815K Buy
+95,172
New +$1.02M ﹤0.01% 2364

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management's SMMT Position: Q1 2026 in Review

Millennium Management reduced its Summit Therapeutics (SMMT) stake by 73% in Q1 2026, selling an estimated $5.54M and leaving 126,273 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3702.

Millennium Management first reported a position in SMMT in Q4 2016 and has held it in 21 quarters since. The position peaked at $36.6M in Q4 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Millennium Management held 126,273 shares of Summit Therapeutics worth $2.39M as of Q1 2026.
  • Millennium Management sold 342,744 Summit Therapeutics shares in Q1 2026, an estimated $5.54M.
  • Summit Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3702 holding.
  • Millennium Management first reported a position in Summit Therapeutics in Q4 2016 and has held it in 21 quarters since.
  • Millennium Management's Summit Therapeutics position peaked at $36.6M in Q4 2024.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.